We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Placental Swabs Found Most Effective for Detection of Maternal Sepsis

By LabMedica International staff writers
Posted on 01 Jan 2024

Over half of maternal deaths occurring in hospitals are attributed to sepsis, a critical condition where an infection spreads beyond local tissue containment, leading to organ failure. More...

Maternal or perinatal sepsis is a significant health concern globally, affecting more than 20 million women and resulting in approximately 17,000 deaths each year. Identifying the infectious agents responsible for these cases is often a complex task. While blood cultures are the preferred diagnostic method, they frequently yield low positive results. Other specimens like vaginal swabs have limited clinical usefulness, and obtaining microbiological cultures from the uterine cavity for antimicrobial guidance is typically challenging. Now, a new study of microbiology specimens used to investigate maternal sepsis has demonstrated that placental swabs could play a vital role in informing antimicrobial therapy decisions.

The study performed by researchers from the University of Limerick (Limerick, Ireland) involved the analysis of nearly 2,000 specimens collected over five and a half years. The team retrospectively assessed the bacterial culture results from various specimens collected as part of a 'septic screen' designed to identify bacteria causing maternal infections leading to sepsis. The specimens included blood, urine, throat swabs, vaginal swabs, and placental swabs. By examining and comparing the results from these specimens for 430 women, the study found that placental swabs were the most effective in detecting the highest number of pathogens.

The study's findings indicate that placental swabs are valuable in identifying potential pathogens from the uterine cavity, which is the most common site of perinatal infections. This discovery is crucial as placental swabs are not routinely examined in many hospitals, meaning vital information that could influence the treatment of these infections might be overlooked. Currently, international guidelines for diagnosing maternal infections are inconsistent, and there is scant information in existing scientific literature about the utilization of placental swabs.

“Maternal sepsis may occur during pregnancy or when a C-section incision, tear or other wound from childbirth becomes infected in the days or weeks after giving birth,” explained Professor Colum Dunne who led the unique new study. “This study provides new information on how sepsis can be detected, and the organisms involved identified early, so that the best approach to successful treatment can be selected.”

Related Links:
University of Limerick


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.